Pfiz­er, Astel­las tout pos­i­tive PhI­II da­ta to po­ten­tial­ly ex­pand Xtan­di la­bel

Pfiz­er and Astel­las are gun­ning to add a fourth in­di­ca­tion to their can­cer drug Xtan­di with Phase III tri­al re­sults re­leased …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.